• A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease

  NCT04004429

  CompletedInterventionalPhase 2Updated Jul 10, 2024
• A Safety & Efficacy Study of Treatment With AP1189 in Rheumatoid Arthritis Patients naïve to DMARD Treatment

  NCT05516979

  CompletedInterventionalPhase 2Updated Nov 7, 2023
• A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate

  NCT05604885

  CompletedInterventionalPhase 2Updated Nov 6, 2024
• A Multiple Dose Study to Evaluate Subcutaneous AMG 108 in Subjects With Rheumatoid Arthritis

  NCT00293826

  CompletedInterventionalPhase 2Updated Mar 5, 2010
• A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis

  NCT03163966

  CompletedInterventionalPhase 2Updated Oct 5, 2021
• Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis

  NCT01285310

  TerminatedInterventionalPhase 2Updated May 8, 2020

ClinicalTrials.gov ID

NCT06671054

Lead Sponsor

SynAct Pharma ApsINDUSTRY

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 2

Enrollment

240Estimated

Last Update Posted

Oct 6, 2025Actual

Start Date

Oct 1, 2024Actual

Primary Completion Date

Dec 2025Estimated

Completion Date

Dec 2025Estimated

Official Title

A Randomized, Double Blind, Placebo-controlled, Dose Response, Phase II, Multicentre Trial to Evaluate the Efficacy and Safety of Oral AP1189 Administered at the Doses of 40, 70, or 100 mg for 12 Weeks in Combination With Methotrexate, in DMARD-naïve Participants With Early Rheumatoid Arthritis and Active Inflammation.

Brief Summary

The study is a randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy and safety of oral AP1189 administered at the doses of 40, 70, or 100 mg for 12 weeks in combination with methotrexate, in DMARD-naïve participants with early rheumatoid arthritis and active inflammation.

Detailed Description

The purpose of the trial is to evaluate the efficacy, safety and tolerability of 12 weeks daily treatment of oral AP1189 at the doses of 40, 70, or 100 mg in combination with oral MTX compared to oral MTX alone.

The aim is to have 240 participants randomized to one of the 4 treatment groups, in a 1:1:1:1 ratio and treated with both AP1189/Placebo and MTX.

• Rheumatoid Arthritis (RA)

• AP1189, 40 mg
• AP1189, 70 mg
• AP1189, 100 mg
• AP1189 matching placebo

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Signed and dated informed consent obtained before undergoing any trial-specific procedure.
• Participants with definite RA diagnosis according to the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria.
• Disease duration no longer than 6 months from diagnosis at the time of Baseline Visit and with a history of RA symptoms which does not exceed 18 months.
• Participants must be naïve to any Disease-modifying anti-rheumatic drugs (DMARDs)
• Participants with at least 6/68 tender and 6/66 swollen joints at Screening Visit and Baseline.
• Participants with "high" disease activity as documented by a Disease Activity Score 28 (DAS28) (C-Reactive Protein - CRP) index score > 5.1 at screening, and Clinical disease activity index (CDAI) >22 at Screening Visit and Baseline.
• Participants with serum high sensitive C-Reactive Protein (hsCRP) ≥3 mg/L at the time of screening.
• Participants positive for serum rheumatoid factor (RF), AND/OR anti-cyclic citrullinated peptide antibodies (anti-CCP). If seronegative RA, hsCRP ≥6 mg/L at the time of screening.
• Willing and able to comply with the scheduled study visits, the treatment plan, and all study procedures.
• Females of childbearing potential must have a negative pregnancy test at screening and again at baseline.
• Sexually active female participants of childbearing potential and male participants are excluded if not practicing two different methods of birth control with their partner during the study and for 90 days after the last dose of study drug or who will not remain abstinent during the study and for 90 days after the last dose.

Exclusion Criteria:

• Functional class IV of Global Functional Status in RA, as defined by the ACR Classification.
• Rheumatic autoimmune disease other than RA, i.e. systemic lupus erythematosus, mixed connective tissue disease, scleroderma, polymyositis, or significant systemic involvement secondary to RA.
• Current inflammatory joint disease other than RA.
• Non-inflammatory type of musculoskeletal condition that in the Investigator's opinion is symptomatic and/or severe enough to interfere with the subject's primary diagnosis of RA or the evaluation of the effect of the study drug.
• Gastrointestinal diseases known to interfere with the absorption or excretion of medications.
• Severe, progressive, or uncontrolled renal, hepatic, hematologic, gastrointestinal, metabolic, endocrine, pulmonary, cardiac or neurologic disease.
• Malignancy active during the 12 months preceding the Screening Visit.
• Acute hepatitis, chronic hepatitis, or detection of any unexplained elevation of serum ALT or AST greater than 1.5-fold ULN, at least twice in the 6 months before the Screening Visit) or HIV infection.
• History of alcohol or drug abuse during the 12 months preceding the Screening Visit.
• Vaccination with live vaccines during the 6 weeks preceding the Screening Visit.
• Haemoglobin <9 g/dL or Haematocrit <30% at the Screening Visit
• White blood cell (WBC) count <3.0 x 109/L at the Screening Visit.
• Absolute neutrophil count <1.2 x 109/L at the Screening Visit.
• Platelet count <100 x 109/L at the Screening Visit.
• Serum alkaline-phosphatase, or gamma-glutamyl-transferase greater than 3-fold ULN; alanine aminotransferase, or aspartate aminotransferase, or total bilirubin greater than 2-fold ULN At the Screening Visit.
• Estimated creatinine clearance less than 45 mL/min/1.73 m2 (MDRD) at the Screening Visit.
• 12-lead electrocardiogram (ECG) with abnormal clinically significant findings, as judged by the Investigator, at the Screening Visit.
• Positive QuantiFERON-in-Tube test (QFG-IT).
• Use of hydroxychloroquine during the 30 weeks preceding the Screening Visit.
• Treatment with any systemic or intraarticular corticosteroid within 6 weeks before the Screening Visit.
• Intermittent use of nonsteroidal anti-inflammatory drugs (NSAIDs). Use of NSAIDs is allowed if used in a stable dose regimen for at least 4 weeks prior to the Screening Visit.
• Use of other investigational drugs/treatments, or enrolment in a clinical trial during the 6 months preceding the Screening Visit.
• Any other clinically relevant disease and condition that, in the opinion of the Investigator, may jeopardize efficacy or safety assessments or may compromise the subject's safety during trial participation.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Triple

Lead Sponsor

SynAct Pharma ApsINDUSTRY

Collaborators

NBCD A/SINDUSTRY

m.wloch-targonska@m2m-badania.pl